MRC Technology Appoints Technology Transfer Director
News Jul 08, 2015
Andrew Farquharson has been appointed Director of Technology Transfer at MRC Technology (MRCT) from 1 September. He will head up the team responsible for identifying, protecting and progressing promising life science research to improve human health.
Andrew has previously held senior Intellectual Property (IP) roles in AstraZeneca UK and USA, supporting the company’s R&D, Business Development and Government Affairs activities. Currently Andrew runs a consultancy practice, providing IP services to a range of life science and pharmaceutical clients and is appointed to the EU Commission’s Expert Group advising on the European Biotech Directive’s impact on patent law and research & development activity.
Commenting on the appointment, Dr Dave Tapolczay, Chief Executive Officer, MRC Technology said: “Andrew’s extensive experience will support our charity’s work to ensure innovative life science research reaches its full potential and benefit a wider range of people. We look forward to having him on board!”
Andrew Farquharson responded: “MRC Technology has a peerless reputation for the development and exploitation of innovative medical research. I am greatly looking forward to joining the MRCT team and using my experience to meet the challenges in ensuring that future innovations are protected and translated into meaningful new therapeutic products made available to patients.”
Alternative to Antibiotics: Antibody Approach for Treating Multidrug-Resistant Bacterial InfectionsNews
Researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. The approach uses antibodies to target the K. pneumoniae protective capsule polysaccharide.READ MORE
Combination Drug Trial Launched to Eradicate B-Cell MalignanciesNews
Researchers at University of California San Diego School of Medicine, in collaboration with local biotechnology company Oncternal Therapeutics, have launched a phase Ib/II clinical trial to evaluate the combined effectiveness of a standard of care drug with a novel monoclonal antibody that target B-cell malignancies, which include leukemias and lymphomas.READ MORE
Monoclonal Antibodies Crucial to Fighting Emerging Infectious DiseasesNews
A new article outlines the potential uses for mAbs as treatments for infectious diseases and as a prevention tool for protecting individuals at risk of infection and slowing disease outbreaks.READ MORE